Oreofe O Odejide1,2, Hajime Uno1, Anays Murillo3, James A Tulsky4,5, Gregory A Abel1,6. 1. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Center for Lymphoma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Tufts University School of Medicine, Boston, Massachusetts. 4. Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts. 5. Division of Palliative Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 6. Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
BACKGROUND: Patients with blood cancers experience high-intensity medical care near the end of life (EOL) and low rates of hospice use; attributes of goals of care (GOC) discussions may partly explain these outcomes. METHODS: By using a retrospective cohort of patients with blood cancer who received care at Dana-Farber Cancer Institute and died in 2014, the authors assessed the potential relationship between timing, location, and the involvement of hematologic oncologists in the first GOC discussion with intensity of care near the EOL and timely hospice use. RESULTS: Among 383 patients, 39.2% had leukemia/myelodysplastic syndromes, 37.1% had lymphoma, and 23.7% had myeloma. Overall, 65.3% of patients had a documented GOC discussion. Of the first discussions, 33.2% occurred >30 days before death, 34.8% occurred in the outpatient setting, and 46.4% included a hematologic oncologist. In multivariable analyses, having the first discussion >30 days before death (odds ratio [OR], 0.37; 95% CI, 0.17-0.81), in the outpatient setting (OR, 0.21; 95% CI, 0.09-0.50), and having a hematologic oncologist present (OR, 0.40; 95% CI, 0.21-0.77) were associated with lower odds of intensive care unit admission ≤30 days before death. The presence of a hematologic oncologist at the first discussion (OR, 3.07; 95% CI, 1.58-5.96) also was associated with earlier hospice use (>3 days before death). CONCLUSIONS: In this large cohort of blood cancer decedents, most initial GOC discussions occurred close to death and in the inpatient setting. When discussions were timely, outpatient, or involved hematologic oncologists, patients were less likely to experience intensive health care use near death and were more likely to enroll in hospice.
BACKGROUND:Patients with blood cancers experience high-intensity medical care near the end of life (EOL) and low rates of hospice use; attributes of goals of care (GOC) discussions may partly explain these outcomes. METHODS: By using a retrospective cohort of patients with blood cancer who received care at Dana-Farber Cancer Institute and died in 2014, the authors assessed the potential relationship between timing, location, and the involvement of hematologic oncologists in the first GOC discussion with intensity of care near the EOL and timely hospice use. RESULTS: Among 383 patients, 39.2% had leukemia/myelodysplastic syndromes, 37.1% had lymphoma, and 23.7% had myeloma. Overall, 65.3% of patients had a documented GOC discussion. Of the first discussions, 33.2% occurred >30 days before death, 34.8% occurred in the outpatient setting, and 46.4% included a hematologic oncologist. In multivariable analyses, having the first discussion >30 days before death (odds ratio [OR], 0.37; 95% CI, 0.17-0.81), in the outpatient setting (OR, 0.21; 95% CI, 0.09-0.50), and having a hematologic oncologist present (OR, 0.40; 95% CI, 0.21-0.77) were associated with lower odds of intensive care unit admission ≤30 days before death. The presence of a hematologic oncologist at the first discussion (OR, 3.07; 95% CI, 1.58-5.96) also was associated with earlier hospice use (>3 days before death). CONCLUSIONS: In this large cohort of blood cancer decedents, most initial GOC discussions occurred close to death and in the inpatient setting. When discussions were timely, outpatient, or involved hematologic oncologists, patients were less likely to experience intensive health care use near death and were more likely to enroll in hospice.
Authors: Jennifer W Mack; Angel Cronin; Nathan Taback; Haiden A Huskamp; Nancy L Keating; Jennifer L Malin; Craig C Earle; Jane C Weeks Journal: Ann Intern Med Date: 2012-02-07 Impact factor: 25.391
Authors: Amy Sexauer; M Jennifer Cheng; Louise Knight; Anthony W Riley; Lauren King; Thomas J Smith Journal: J Palliat Med Date: 2014-01-02 Impact factor: 2.947
Authors: Maria Dans; Thomas Smith; Anthony Back; Justin N Baker; Jessica R Bauman; Anna C Beck; Susan Block; Toby Campbell; Amy A Case; Shalini Dalal; Howard Edwards; Thomas R Fitch; Jennifer Kapo; Jean S Kutner; Elizabeth Kvale; Charles Miller; Sumathi Misra; William Mitchell; Diane G Portman; David Spiegel; Linda Sutton; Eytan Szmuilowicz; Jennifer Temel; Roma Tickoo; Susan G Urba; Elizabeth Weinstein; Finly Zachariah; Mary Anne Bergman; Jillian L Scavone Journal: J Natl Compr Canc Netw Date: 2017-08 Impact factor: 11.908
Authors: Oreofe O Odejide; Angel M Cronin; Craig C Earle; Ann S LaCasce; Gregory A Abel Journal: J Natl Cancer Inst Date: 2015-10-05 Impact factor: 13.506
Authors: Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Craig C Earle; Mary Beth Landrum; Jeffrey M Souza; Bridget A Neville; Jane C Weeks; John Z Ayanian Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Timothy Gilligan; Nessa Coyle; Richard M Frankel; Donna L Berry; Kari Bohlke; Ronald M Epstein; Esme Finlay; Vicki A Jackson; Christopher S Lathan; Charles L Loprinzi; Lynne H Nguyen; Carole Seigel; Walter F Baile Journal: J Clin Oncol Date: 2017-09-11 Impact factor: 44.544
Authors: Daniel Hong; Lauren C Das; Ellen Daily; Stacie K Levine; Olwen M Hahn; Stanley L Liauw; Daniel W Golden; Christina H Son Journal: Support Care Cancer Date: 2021-05-25 Impact factor: 3.603
Authors: Andrew S Epstein; Michael Riley; Judith E Nelson; Camila Bernal; Steven Martin; Han Xiao Journal: Cancer Date: 2022-07-22 Impact factor: 6.921
Authors: Kah Poh Loh; Eric M McLaughlin; Jessica L Krok-Schoen; Oreofe O Odejide; Areej El-Jawahri; Lihong Qi; Aladdin H Shadyab; Lisa G Johnson; Electra D Paskett Journal: J Cancer Surviv Date: 2022-08-18 Impact factor: 4.062
Authors: Clark DuMontier; Hajime Uno; Tammy Hshieh; Guohai Zhou; Richard Chen; Emily S Magnavita; Lee Mozessohn; Houman Javedan; Richard M Stone; Robert J Soiffer; Jane A Driver; Gregory A Abel Journal: Haematologica Date: 2022-05-01 Impact factor: 11.047
Authors: P Connor Johnson; Netana H Markovitz; Alisha Yi; Richard A Newcomb; Hermioni L Amonoo; Ashley M Nelson; Matthew J Reynolds; Julia Rice; Mitchell W Lavoie; Oreofe O Odejide; Ryan D Nipp; Areej El-Jawahri Journal: J Palliat Med Date: 2021-11-01 Impact factor: 2.947
Authors: Marissa LoCastro; Andrea M Baran; Jane L Liesveld; Eric Huselton; Michael W Becker; Kristen Marie O'Dwyer; Omar S Aljitawi; Megan Baumgart; Eric Snyder; Benzi Kluger; Kah Poh Loh; Jason H Mendler Journal: Blood Adv Date: 2021-12-28